Intrauterine adhesions Medical Services in China

Intrauterine adhesions (IUA), also known as Asherman’s syndrome, are fibrous bands of scar tissue that form within the uterine cavity, leading to partial or complete obliteration of the endometrial space. These adhesions result from trauma-induced damage to the basal layer of the endometrium—most commonly following dilation and curettage (D&C) after miscarriage or postpartum hemorrhage, but also after uterine surgery (e.g., myomectomy, cesarean section), infection (chronic endometritis), or radiation therapy. Pathogenesis centers on defective re-epithelialization: injury disrupts the delicate balance between tissue repair and fibrosis, triggering excessive collagen deposition by activated fibroblasts and myofibroblasts, often exacerbated by impaired angiogenesis and reduced stem cell recruitment in the damaged endometrium. Epidemiologically, IUA affects an estimated 1.5–22% of women undergoing D&C for pregnancy-related complications, with higher prevalence (up to 30%) among those with recurrent pregnancy loss or repeated uterine instrumentation. Risk factors include multiple D&Cs, surgical termination in the second trimester, history of pelvic tuberculosis (especially in endemic regions), severe intrauterine infection, and possibly genetic predisposition to aberrant wound healing. Clinically, symptoms range from amenorrhea or hypomenorrhea (most common), cyclic pelvic pain (due to trapped menstrual blood), infertility, and recurrent pregnancy loss—though some cases remain asymptomatic until fertility evaluation. The condition profoundly impacts quality of life: women often experience emotional distress, anxiety about fertility, sexual dysfunction due to pain or fear of conception failure, and diminished self-perception related to reproductive identity. Untreated IUA carries high risks of obstetric complications—including placenta accreta spectrum disorders, preterm birth, and intrauterine growth restriction—if pregnancy occurs. Early diagnosis via saline infusion sonohysterography (SIS) or hysteroscopy is critical; hysteroscopy remains the gold standard for both diagnosis and therapeutic intervention. Management aims not only to restore uterine anatomy but also to regenerate functional endometrium—requiring a multimodal approach combining mechanical adhesiolysis, intrauterine barrier placement (e.g., hyaluronic acid gel or balloon catheter), hormonal support (estrogen-progesterone regimens), and sometimes adjunctive therapies like platelet-rich plasma (PRP) or stem cell applications in refractory cases. Long-term follow-up with repeat hysteroscopy is essential to assess endometrial recovery and prevent recurrence, which occurs in 20–62% of moderate-to-severe cases without optimal adjuvant therapy.

Intrauterine adhesions (IUAs), also known as Asherman syndrome, represent a pathological condition characterized by the formation of fibrous bands—ranging from thin, avascular strands to dense, vascularized scar tissue—within the uterine cavity. These adhesions typically result from trauma to the endometrial basal layer, most commonly following dilation and curettage (D&C) for miscarriage or postpartum hemorrhage, but may also arise after cesarean delivery, myomectomy, uterine infection (e.g., genital tuberculosis), or chronic endometritis. Clinical manifestations include amenorrhea or hypomenorrhea, recurrent pregnancy loss, implantation failure in assisted reproductive technology (ART), and infertility. Diagnosis relies on hysteroscopy—the gold standard—as saline infusion sonography (SIS) and transvaginal ultrasound serve only as adjunctive screening tools. Treatment is stratified according to adhesion severity (classified using the European Society of Gynaecological Endoscopy [ESGE] or American Fertility Society [AFS] scoring systems), symptom burden, and reproductive goals.

Conservative management is reserved for asymptomatic patients with mild, non-obstructive adhesions and no fertility concerns—or for those who decline or are not candidates for surgery. It emphasizes surveillance and hormonal modulation to support endometrial regeneration. Patients undergo serial clinical evaluation every 3–6 months, including menstrual history assessment and pelvic ultrasound to monitor endometrial thickness and pattern. While no randomized trials support routine conservative therapy alone for moderate-to-severe IUAs, low-dose estrogen-progestin regimens (e.g., estradiol valerate 2 mg daily × 21 days plus medroxyprogesterone acetate 10 mg daily × 10 days) may be trialed for 2–3 cycles in select cases with minimal synechiae and preserved basal endometrium. However, evidence for efficacy remains limited, and conservative approaches do not address mechanical obstruction or restore cavity architecture.

Pharmacologic interventions serve primarily as adjuncts—not standalone therapies. Estrogen therapy (typically oral or transdermal estradiol 4–6 mg/day for 2–4 weeks postoperatively) aims to stimulate endometrial proliferation and inhibit fibroblast collagen synthesis. A meta-analysis of 12 RCTs demonstrated that postoperative estrogen significantly improves endometrial thickness (mean difference +2.1 mm; 95% CI 1.4–2.8) and reduces adhesion recurrence (RR 0.57; 95% CI 0.41–0.79). Antibiotics (e.g., doxycycline 100 mg BID × 7 days) are routinely administered perioperatively to mitigate infection-related fibrosis. Emerging agents under investigation include intrauterine hyaluronic acid gels (e.g., Hyalobarrier®), which act as physical barriers to re-adhesion formation; studies report ~30% relative reduction in recurrence versus placebo when applied immediately after adhesiolysis. Pentoxifylline and aspirin have been explored for antifibrotic and antiplatelet effects, respectively, though robust clinical data are lacking. Notably, gonadotropin-releasing hormone agonists (GnRHa) are contraindicated preoperatively, as they induce hypoestrogenic atrophy that impairs endometrial healing and increases intraoperative bleeding risk.

Surgical treatment—hysteroscopic adhesiolysis—is the cornerstone of definitive management. Performed under direct visualization using either rigid or flexible hysteroscopes, it involves meticulous lysis of adhesions using microscissors, blunt dissection, or low-power monopolar/bipolar electrodes. Cold instrumentation is preferred for filmy adhesions to minimize thermal injury; electrocautery is reserved for dense, vascularized bands with strict attention to depth control. The procedure requires expertise in recognizing the endometrial-myometrial junction to avoid perforation or excessive myometrial resection. In severe cases (ESGE grade III–IV), staged surgery may be indicated: initial lysis followed by estrogen priming and repeat hysteroscopy in 4–6 weeks to address residual or recurrent adhesions. Intraoperative ultrasound guidance enhances safety during deep dissection. Postoperative intrauterine device (IUD) placement is discouraged due to infection and embedment risks; instead, balloon catheters (e.g., Foley 10–12 Fr) inflated with 2–3 mL saline are placed for 5–7 days to maintain cavity separation, with proven superiority over IUDs in recurrence prevention (OR 0.32; 95% CI 0.18–0.57).

China offers distinct advantages in IUA management, particularly within specialized Reproductive Medicine Departments. First, high-volume centers—such as Peking University Third Hospital, Shanghai Jiao Tong University Affiliated International Peace Maternity and Child Health Hospital, and Nanjing Drum Tower Hospital—perform >500 hysteroscopic adhesiolyses annually, fostering unparalleled operator proficiency and standardized protocols aligned with ESGE guidelines. Second, China leads in translational innovation: domestically developed hysteroscopic platforms (e.g., Wisonic HD-3000) integrate real-time AI-assisted tissue differentiation, improving identification of residual adhesions. Third, integrated care models combine reproductive endocrinology, reproductive immunology, and chronic endometritis diagnostics (via CD138 immunohistochemistry and PCR-based endometrial microbiome profiling), enabling personalized postoperative strategies. Fourth, cost-effectiveness is notable: comprehensive surgical management—including hysteroscopy, histopathology, and 3-month follow-up—averages USD $1,800–$2,500, substantially lower than comparable care in Western Europe or North America, without compromising outcomes. Finally, national registries (e.g., China IUA Registry) facilitate longitudinal outcome tracking, informing evidence-based refinements in adjuvant therapy selection.

Post-treatment recovery necessitates structured, multidisciplinary follow-up. Patients receive oral estradiol (4 mg/day) for 2 weeks, then combined estrogen-progestin for an additional 2 weeks, followed by a withdrawal bleed. A diagnostic hysteroscopy is scheduled at 6–8 weeks to assess cavity patency and endometrial quality; if adhesions recur, early reintervention yields superior outcomes. Lifestyle counseling includes avoidance of vaginal intercourse and tampon use for 4 weeks, smoking cessation (nicotine impairs angiogenesis), and nutritional optimization (adequate vitamin E, omega-3 fatty acids, and iron to support endometrial repair). For patients pursuing conception, ovulation induction or IVF is deferred until two consecutive normal menstrual cycles and confirmed cavity integrity. Pregnancy rates after successful adhesiolysis range from 45% (mild) to 25% (severe); live birth rates correlate strongly with postoperative endometrial thickness ≥7 mm and absence of central adhesions. Long-term monitoring includes annual transvaginal ultrasound and endometrial biopsy in women with prior severe IUAs to screen for atrophy or hyperplasia. Psychological support is integral, given the high prevalence of anxiety and depression linked to infertility and recurrent loss. Ultimately, optimal IUA management demands individualized, stage-specific intervention, rigorous surgical technique, evidence-based adjuvant therapy, and sustained reproductive health surveillance.